Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMONYSE / NASDAQHealthcareLarge cap

$669.54-$19.21 (-2.8%)

Last close · Data as of Nov 20, 2026

Market cap
$179.1B
P/E
26.7x
EV / EBITDA
18.1x
Revenue
$44.6B
Net margin
15.0%
ROCE
9.4%

+16.9% over the last year

Thermo Fisher Scientific Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-2.6%
3M
+6.7%
6M
+48.2%
1Y
+16.9%
5Y
+5.3%

52-week range

Day change -$19.21 (-2.8%) from $689 to $670 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TMO, bought on each weekday since 2021.

News & filings

What Thermo Fisher Scientific filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 6.2 times interest costs.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.

Read moreShow less

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Shares outstanding
376.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$179.1B
P/E
26.7x
P/B
3.4x
EV / EBITDA
18.1x
EV / Sales
4.7x
P/S
4.0x
52-week high
$721.63
52-week low
$438.34

Profitability

Operating margin
18.2%
Net margin
15.0%
EBITDA margin
25.8%
ROE
12.6%
ROCE
9.4%
ROA
6.1%
Asset turnover
0.40

Growth

Revenue
$44.6B
Revenue growth, 1Y
3.9%
Revenue CAGR, 3Y
-0.3%
Net profit growth, 1Y
5.8%
Free cash flow
$6.3B

Solvency

Current ratio
1.89
Debt / Equity
0.74
Debt / Assets
0.36
CFO / Net profit
1.17
Cash / Market cap
5.6%

Where the revenue went

Of every $100 of FY2025 revenue, $15 was left as net income.

Thermo Fisher Scientific Inc. income statement flow, FY2025
Thermo Fisher Scientific Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$26.3B
RevenueGross profit$18.2B
Gross profitResearch and development$1.4B
Gross profitSelling, general and administrative$8.7B
Gross profitOperating income$8.1B
Operating incomePretax income$7.3B
Operating incomeInterest and other expense$802.0M
Pretax incomeTax and other$604.0M
Pretax incomeNet income$6.7B

Revenue and net profit

Revenue grew 3.9% in FY2025; net profit is the dashed line.

Thermo Fisher Scientific Inc. revenue and net profit by fiscal year
Thermo Fisher Scientific Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$44.9B$7.0B
FY2023$42.9B$6.0B
FY2024$42.9B$6.3B
FY2025$44.6B$6.7B

Cash flows

FY2025: $7.8B from operations, $6.3B free after investment (dashed).

Thermo Fisher Scientific Inc. operating and free cash flow by fiscal year
Thermo Fisher Scientific Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$9.2B$6.9B
FY2023$8.4B$6.9B
FY2024$8.7B$7.3B
FY2025$7.8B$6.3B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$44.6B+3.9%1Y
EBITDA
$11.5B-0.2%1Y
Net profit
$6.7B+5.8%1Y
Cash from operations
$7.8B-9.8%1Y
Free cash flow
$6.3B-13.4%1Y
Revenue CAGR, 3Y
-0.3%
Net profit CAGR, 3Y
-1.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$44.6B$11.5B$6.7B$6.3B12.6%+3.9%+5.8%

Monthly returns

Month-by-month returns of TMO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$110.3B
Liabilities$56.8B
Equity$53.5B
Paid-in capital$18.6B
Retained earnings$59.2B
Treasury stock$22.3B
Minority interest$129.0M

Market cap against peers

8 peers: same sector, nearest by size.

  1. Amgen Inc.$186.5B
  2. Thermo Fisher Scientific Inc. (this company)$179.1B

Peers map

Healthcare companies placed by value, growth and quality; TMO highlighted.

P/E against peers

TMO trades at 26.7x earnings against a peer median of 24.2x (a 10% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Thermo Fisher Scientific Inc.TMOthis companyP/E ↑ premium$179.1B26.7x3.4x12.6%18.1x
Amgen Inc.AMGN$186.5B24.2x21.5x89.1%13.7x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Peer median—24.2x4.6x14.3%13.6x

Year-to-date ROI

TMO since 1 January, against earlier years.

Historical volatility

TMO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Thermo Fisher Scientific Inc. operating margin by fiscal year
Thermo Fisher Scientific Inc. operating margin by fiscal year
DateOperating margin
FY202218.9%
FY202317.1%
FY202418.0%
FY202518.2%
LineFY2025
Cost of revenueCost Of Revenue$26.3B
Gross profitGross Profit$18.2B
Operating expensesOperating Expense$10.1B
Research and developmentResearch And Development$1.4B
Selling, general and administrativeSelling General And Administration$8.7B
Total expensesTotal Expenses$36.4B
Pretax incomePretax Income$7.3B

Learn while you research

Academy chapters picked for Thermo Fisher Scientific Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →